Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
57 pending office actions • 17 clients • 53 examiners • 37 art units • 0 of 57 (0%) have an AI response strategy ready • 51 patents granted in the last 365 days
Joseph R. Baker, APC specializes in Biotechnology & Pharmaceuticals. The firm has 1965 career applications. Its resolved allowance rate is 83.96 percent. It averages 4.29 office actions per allowance. There are 50 pending office actions.
The 83.96 percent allowance rate is the outcome for its 1965 career applications. The average of 4.29 office actions per allowance indicates the typical number of responses for an allowance. The 50 pending office actions show the current state of the firm's biotechnology practice.
Based on the USPTO statutory response window for each pending office action. 24 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 24 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (11%) |
| §103 only | 17 (30%) |
| §112 only | 2 (4%) |
| Double-patenting only | 4 (7%) |
| Double-patenting + other | 4 (7%) |
| Multi-statute (no §101) | 23 (40%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THOMAS, KAREEN KAY | 2 | 77.0% | +17.1% |
| CHHAY, BONIRATH | 2 | 83.3% | +0.0% |
| RODRIGUEZ, VICENTE M | 2 | 77.2% | +15.8% |
| THUESON, HANNA MARIE | 2 | 76.7% | +28.2% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| BUI, DUNG H | 1 | 77.8% | +25.4% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| MEYERS, ELIZABETH ANNE | 1 | 23.5% | +92.9% |
| SINGH, SATYENDRA K | 1 | 61.5% | +67.7% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18104770 | SCANNING MULTIPLE LIDAR SYSTEM OUTPUT SIGNALS | THATCHER, CLINT A | 60d overdue |
| 18072666 | CONTROL OF SIGNAL CHIRP IN LIDAR SYSTEMS | CHILTON, CLARA GRACE | 50d overdue |
| 18026287 | HYBRID PROTOCOLS AND BARCODING SCHEMES FOR MULTIPLE SEQUENCING TECHNOLOGIES | DAUNER, JOSEPH G | 35d overdue |
| 18290679 | PTPRS IN AUTOIMMUNITY | KRUSE, DAVID H | 28d overdue |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 8d overdue |
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | WESTERBERG, NISSA M | 9d |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | CRAIGO, BAHAR ALAWI | 23d |
| 18297593 | RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS | LEE, JIA-HAI | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18904689 | POLYESTER RESIN CLOSURES FOR CONTAINERS | THOMAS, KAREEN KAY | 84d |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | THUESON, HANNA MARIE | 86d |
| 19389742 | PRESSURE DOME CAP | THOMAS, KAREEN KAY | — |
| 18940334 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | JACKSON-TONGUE, LAKIA J | — |
| 18852444 | MEMBRANES INCORPORATED WITH POROUS POLYMER FRAMEWORKS | BUI, DUNG H | — |
| 18826093 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | OGUNBIYI, OLUWATOSIN A | — |
| 18841637 | ENDOSOMAL CLEAVABLE HYDROPHILIC-MASKED CATIONIC CHARGE DELIVERY VEHICLES | MEYERS, ELIZABETH ANNE | — |
| 18720403 | CARBON FIXATION SYSTEM | SINGH, SATYENDRA K | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of California | 20 |
| SiLC Technologies, Inc. | 11 |
| LDN Pharma | 5 |
| VERITEQUE USA, INC. | 3 |
| Randox | 3 |
| Origin Materials Operating, Inc. | 2 |
| Prokarium Limited | 2 |
| Abintus Bio, Inc. | 2 |
| Phase Biolabs Ltd. | 1 |
| ILLUMINA, INC. | 1 |
| Toragen, Inc. | 1 |
| SAGA UNIVERSITY | 1 |
| Ohara Pharmaceutical Co., Ltd. | 1 |
| Dr. Sabrina Ltd. | 1 |
| Thyas Co. Ltd. | 1 |
| University of Southern California | 1 |
| Pennog Limited | 1 |
| Art Unit | Apps |
|---|---|
| 1645 | 5 |
| 3645 | 4 |
| 3736 | 2 |
| 1632 | 2 |
| 1628 | 2 |
| 1633 | 2 |
| 1638 | 2 |
| 1618 | 2 |
| 1611 | 1 |
| 1657 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19389742 | PRESSURE DOME CAP | Origin Materials Operating, Inc. | THOMAS, KAREEN KAY | 3736 | §103 | Final Rejection | — | Pending | Nov 14, 2025 |
| 18940334 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | Prokarium Limited | JACKSON-TONGUE, LAKIA J | §112DP | Non-Final OA | — | Pending | Nov 07, 2024 | |
| 18860177 | OSMOLYSIS-BASED RECOVERY OF BIOMACROMOLECULES FROM ENGINEERED HALOTOLERANT MICROORGANISMS | The Regents of the University of California | CHHAY, BONIRATH | §101§102§103§112 | Non-Final OA | — | Pending | Oct 25, 2024 | |
| 18904689 | POLYESTER RESIN CLOSURES FOR CONTAINERS | Origin Materials Operating, Inc. | THOMAS, KAREEN KAY | 3736 | §103 | Non-Final OA | 84d | Pending | Oct 02, 2024 |
| 18852444 | MEMBRANES INCORPORATED WITH POROUS POLYMER FRAMEWORKS | The Regents of the University of California | BUI, DUNG H | §102§103 | Non-Final OA | — | Pending | Sep 28, 2024 | |
| 18826093 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | The Regents of the University of California | OGUNBIYI, OLUWATOSIN A | 1645 | §103 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18841637 | ENDOSOMAL CLEAVABLE HYDROPHILIC-MASKED CATIONIC CHARGE DELIVERY VEHICLES | The Regents of the University of California | MEYERS, ELIZABETH ANNE | 1611 | §102§103§112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18720403 | CARBON FIXATION SYSTEM | Phase Biolabs Ltd. | SINGH, SATYENDRA K | 1657 | §103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18716430 | COMBINATION CANCER THERAPY | Prokarium Limited | DUFFY, PATRICIA ANN | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jun 04, 2024 |
| 18664102 | DIGITAL MICROFLUIDIC SYSTEM FOR SINGLE-CELL ISOLATION AND CHARACTERIZATION OF ANALYTES | Illumina, Inc. | TSUI, YUNG-SHENG M | §102§112DP | Non-Final OA | — | Pending | May 14, 2024 | |
| 18660141 | INCREASING RANGE OF IMAGING SYSTEMS | Silc Technologies, Inc. | HAUT, EVAN HARRISON | §103§112 | Non-Final OA | — | Pending | May 09, 2024 | |
| 18655189 | CONCURRENT LIDAR MEASUREMENTS OF A REGION IN A FIELD OF VIEW | Silc Technologies, Inc. | MANG, LAL C | 2857 | DP | Non-Final OA | — | Pending | May 03, 2024 |
| 18644030 | IMAGING SYSTEM WITH INCREASED EFFICIENCY | Silc Technologies, Inc. | GARDINER, JOSH CHARLES | §103§112 | Non-Final OA | — | Pending | Apr 23, 2024 | |
| 18611334 | PORTABLE LIQUID ANALYZER | VERITEQUE USA, INC. | SINES, BRIAN J | 1796 | §103Other | Final Rejection | — | Pending | Mar 20, 2024 |
| 18595334 | DEVICE DETECTION SYSTEM | Silc Technologies, Inc. | RODRIGUEZ, VICENTE M | §102§103§112 | Non-Final OA | — | Pending | Mar 04, 2024 | |
| 18684155 | ANTIGEN PRESENTING CELL/TARGET CELL HYBRIDOMA-DERIVED VACCINES | The Regents of the University of California | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18681457 | GENETICALLY ENGINEERED CELL-DERIVED VACCINES | The Regents of the University of California | CHHAY, BONIRATH | 1645 | §103§112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18290679 | PTPRS IN AUTOIMMUNITY | The Regents of the University of California | KRUSE, DAVID H | 1663 | §102§112 | Final Rejection | 28d overdue | Pending | Jan 19, 2024 |
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | Ldn Pharma Limited | SAMSELL, RILLA MARIE | 1624 | DP | Final Rejection | 20d | Pending | Dec 21, 2023 |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | Ldn Pharma Limited | VALENROD, YEVGENY | 1628 | §112 | Non-Final OA | 83d | Pending | Dec 20, 2023 |
| 18539251 | AMPLIFICATION OF SIGNALS IN IMAGING SYSTEMS | Silc Technologies, Inc. | DECARIA, MICHAEL ALEX | 4100 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18568467 | BROAD SPECTRUM DETECTION KITS | VERITEQUE USA, INC. | ALABI, OYELEYE A | 1797 | §101§103 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18285000 | MODIFIED VIRUSES AND VIRAL PARTICLES, METHODS OF MAKING, AND USES THEREOF | The Regents of the University of California | GU, QINHUA | 1633 | §103 | Final Rejection | 42d | Pending | Sep 29, 2023 |
| 18283652 | METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE | Randox Teoranta | SAOUD, CHRISTINE J | 1645 | §101§102§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18234826 | 2-S RIMANTADINE AND 2-R RIMANTADINE FOR TREATING CANCER | Toragen, Inc. | YOO, SUN JAE | 1621 | §103 | Final Rejection | 28d | Pending | Aug 16, 2023 |
| 18231114 | AUTOIMMUNE THERAPY | Ldn Pharma Limited | COPPINS, JANET L | 1628 | §103§112 | Non-Final OA | 83d | Pending | Aug 07, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | Ldn Pharma Limited | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | 49d overdue | Pending | Jul 21, 2023 |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | Saga University | CRAIGO, BAHAR ALAWI | 1699 | §102§103§112 | Non-Final OA | 23d | Pending | Jul 11, 2023 |
| 18271832 | RIBOZYME-ACTIVATED RNA CONSTRUCTS AND USES THEREOF | The Regents of the University of California | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112DPOther | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18297593 | RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS | The Regents of the University of California | LEE, JIA-HAI | 1658 | §102§112 | Final Rejection | 26d | Pending | Apr 07, 2023 |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | The Regents of the University of California | THUESON, HANNA MARIE | 1638 | §102§103 | Non-Final OA | 86d | Pending | Mar 27, 2023 |
| 18026287 | HYBRID PROTOCOLS AND BARCODING SCHEMES FOR MULTIPLE SEQUENCING TECHNOLOGIES | The Regents of the University of California | DAUNER, JOSEPH G | 1682 | §102§103§112 | Final Rejection | 35d overdue | Pending | Mar 14, 2023 |
| 18022630 | siRNA AND USE THEREOF | Ohara Pharmaceutical Co., Ltd. | SHIN, DANA H | 1635 | Other | Non-Final OA | — | Pending | Feb 22, 2023 |
| 18104770 | SCANNING MULTIPLE LIDAR SYSTEM OUTPUT SIGNALS | Silc Technologies, Inc. | THATCHER, CLINT A | 3645 | §102§103 | Final Rejection | 60d overdue | Pending | Feb 01, 2023 |
| 18100204 | IMMUNOMODULATORY OLIGOSACCHARIDES | The Regents of the University of California | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Jan 23, 2023 |
| 18006011 | GUN SHOT RESIDUE FIELD KIT | VERITEQUE USA, INC. | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | 16d overdue | Pending | Jan 19, 2023 |
| 18016432 | RECOMBINANT MICROORGANISMS | The Regents of the University of California | DICKENS, AMELIA NICOLE | 1645 | §112 | Non-Final OA | — | Pending | Jan 16, 2023 |
| 18097261 | OPTICAL BRIDGES FOR PHOTONIC INTEGRATED CIRCUITS | Silc Technologies, Inc. | TAVLYKAEV, ROBERT FUATOVICH | 2896 | §103 | Non-Final OA | 30d overdue | Pending | Jan 15, 2023 |
| 18076001 | ANTI-AGING DERMATOLOGICAL COMPOSITIONS | Dr. Sabrina Ltd. | WRIGHT, SARAH C | 1619 | §103 | Final Rejection | 7d | Pending | Dec 06, 2022 |
| 18074402 | ENGINEERED VASCULARIZED ORGANOIDS | The Regents of the University of California | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | — | Pending | Dec 02, 2022 |
| 18072666 | CONTROL OF SIGNAL CHIRP IN LIDAR SYSTEMS | Silc Technologies, Inc. | CHILTON, CLARA GRACE | 3645 | §103§112 | Final Rejection | 50d overdue | Pending | Nov 30, 2022 |
| 17924480 | METHOD FOR PRODUCING REGENERATED T CELLS VIA IPS CELLS | Thyas Co. Ltd. | SPENCE, JENNIFER SUZANNE | 1633 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2022 |
| 17924080 | VECTORS AND METHODS FOR IN VIVO TRANSDUCTION | Abintus Bio, Inc. | JACKSON III, WALTER | 1674 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17970508 | IDENTIFICATION OF CHIRP RATES | Silc Technologies, Inc. | NAPIER, JAMES WILBURN | 3645 | §102§103 | Final Rejection | — | Pending | Oct 20, 2022 |
| 17920379 | UNIVERSAL PRIMERS FOR DETECTION OF BACTERIA, FUNGI AND EUKARYOTIC MICROORGANISMS | The Regents of the University of California | BERTAGNA, ANGELA MARIE | 1681 | §101§102§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 18048386 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | The Regents of the University of California | SZPERKA, MICHAEL EDWARD | 1641 | §102§112DP | Non-Final OA | 26d | Pending | Oct 20, 2022 |
| 17912313 | SCREENING METHODS TO IDENTIFY SMALL MOLECULE COMPOUNDS THAT PROMOTE OR INHIBIT THE GROWTH OF CIRCULATING TUMOR CELLS, AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17786913 | BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF CANNABINOIDS AND OTHER PRENYLATED COMPOUNDS | The Regents of the University of California | RAMIREZ, DELIA M | 1652 | DP | Non-Final OA | 43d overdue | Pending | Jun 17, 2022 |
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | Randox Laboratories Ltd. | WESTERBERG, NISSA M | 1618 | §101§103§112 | Final Rejection | 9d | Pending | May 06, 2022 |
| 17584129 | METHODS AND THERAPIES FOR TREATING ATHEROSCLEROSIS AND/OR HYPERLIPIDEMIA USING OLIGOSACCHARIDES | The Regents of the University of California | OLSON, ANDREA STEFFEL | 1693 | §102§103Other | Final Rejection | 35d | Pending | Jan 25, 2022 |
| 17617278 | BIOCIDAL COMPOSITE MATERIAL | Pennog Limited | TRUONG, QUANGLONG N | 1615 | §103 | Non-Final OA | 84d | Pending | Dec 07, 2021 |
| 17465835 | USE OF MULTIPLE STEERING MECHANISMS IN SCANNING | Silc Technologies, Inc. | RICHTER, KARA MARIE | 3645 | §103 | Non-Final OA | — | Pending | Sep 02, 2021 |
| 17435911 | METHOD FOR DETERMINING EFFICACY | Ldn Pharma Limited | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | 8d overdue | Pending | Sep 02, 2021 |
| 17419239 | CAR T CELL METHODS AND CONSTRUCTS | Abintus Bio, Inc. | KIM, TAEYOON | 1631 | §103§112 | Final Rejection | — | Pending | Jun 28, 2021 |
| 17294358 | DETECTION OF BLADDER CANCER | Randox Laboratories Ltd. | MONTGOMERY, ANN Y | 1678 | §101§103 | Non-Final OA | 28d | Pending | May 14, 2021 |
| 17221770 | USE OF CIRCULATOR IN LIDAR SYSTEM | Silc Technologies, Inc. | RODRIGUEZ, VICENTE M | 3642 | §103 | Final Rejection | — | Pending | Apr 02, 2021 |
| 17025836 | GENERATION OF HUMAN iPS CELLS BY A SYNTHETIC SELF-REPLICATIVE RNA | The Regents of the University of California | DHAR, MATASHA | 1632 | DP | Final Rejection | — | Pending | Sep 18, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial